Moderna on Tuesday said its vaccine that targets respiratory syncytial virus is effective at preventing disease in older adults. The vaccine was 83.7% effective at preventing lower respiratory tract disease, defined as two or more symptoms, in people ages 60 and older, according to the Boston biotech company. It was 82.4% effective at preventing lower